Melatonin

Fisetin, 1400W, celecoxib (CB) were purchased from Sigma-Aldrich (St. Louis, USA). Melatonin was purchased from J&K Chemical Ltd. All reagents were dissolved in DMSO as the initial concentrate and diluted with medium before adding to the cell.

Melatonin was purchased from J&K, Chemical Ltd. Vemurafenib was obtained from Selleck (PLX4032) and dissolved in dimethyl sulphoxide (DMSO) before addition to the complete cell culture medium. For the experiment, the solution of Melatonin (1 M) and Vemurafenib (VE) (10 mM) in DMSO was prepared and kept at 4 °C for further dilution in culture medium to maintain stability of used drugs. The InSolution™ NF-κB Activation Inhibitor controlling the biological activity of NF-κB (481407) was bought from Merck Millipore. Antibodies against β-catenin, MMP-1, MMP-9, Apaf-1 were purchased from Santa Cruz (USA). The antibodies against β-actin, IKKα, IKKβ, p-IKKα/β, IκB-α, p-IκB-α, cleaved caspase-3, cleaved caspase-9, cleaved PARP, Bcl-2, NF-κB p50, p65, p-PDK1, p-PTEN, p-AKT and AKT were purchased from Cell Signaling Technology (USA). The anti-TFIIB, E-cadherin antibodies were purchased from Proteintech group (USA), and anti-iNOS antibody was purchased from Wanlei Biotechnology (China). The anti-BRAF V600E antibody was purchased from Omnimabs (USA).